| Christine Georgine Saad, MD | |
|
401 N 17th St, Ste 103, Allentown, PA 18104-5034 | |
| (610) 969-3070 | |
| (610) 969-3073 |
| Full Name | Christine Georgine Saad |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 22 Years |
| Location | 401 N 17th St, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982648226 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152WC0802X | Optometrist - Corneal And Contact Management | MD428749 (Pennsylvania) | Secondary |
| 207W00000X | Ophthalmology | MD428749 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lehigh Valley Physician Group | 3072425123 | 1763 |
News Archive
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
A researcher from the University of Birmingham has co-developed a device to significantly improve the maternity aftercare of many new mothers - and the invention could also help lead the way in forensic investigations.
The number and percentage of uninsured U.S. residents declined in 2007 to 45.7 million people, or 15.3% of the population, according to an annual U.S. Census Bureau report released Tuesday, USA Today reports (Cauchon/Appleby, USA Today, 8/27).
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).
California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy (FSMA) announced today that CSC has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for approval to commence a Phase I safety study on a jointly-developed stem cell-derived motor neuron transplantation therapy for Spinal Muscular Atrophy (SMA) Type I.
› Verified 2 days ago
| Provider Name | Lehigh Valley Physician Group |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
A researcher from the University of Birmingham has co-developed a device to significantly improve the maternity aftercare of many new mothers - and the invention could also help lead the way in forensic investigations.
The number and percentage of uninsured U.S. residents declined in 2007 to 45.7 million people, or 15.3% of the population, according to an annual U.S. Census Bureau report released Tuesday, USA Today reports (Cauchon/Appleby, USA Today, 8/27).
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).
California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy (FSMA) announced today that CSC has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for approval to commence a Phase I safety study on a jointly-developed stem cell-derived motor neuron transplantation therapy for Spinal Muscular Atrophy (SMA) Type I.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christine Georgine Saad, MD Po Box 783311, Philadelphia, PA 19178-3311 Ph: () - | Christine Georgine Saad, MD 401 N 17th St, Ste 103, Allentown, PA 18104-5034 Ph: (610) 969-3070 |
News Archive
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
A researcher from the University of Birmingham has co-developed a device to significantly improve the maternity aftercare of many new mothers - and the invention could also help lead the way in forensic investigations.
The number and percentage of uninsured U.S. residents declined in 2007 to 45.7 million people, or 15.3% of the population, according to an annual U.S. Census Bureau report released Tuesday, USA Today reports (Cauchon/Appleby, USA Today, 8/27).
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).
California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy (FSMA) announced today that CSC has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for approval to commence a Phase I safety study on a jointly-developed stem cell-derived motor neuron transplantation therapy for Spinal Muscular Atrophy (SMA) Type I.
› Verified 2 days ago